Literature DB >> 24936058

Role of protein phosphatase 1 in dephosphorylation of Ebola virus VP30 protein and its targeting for the inhibition of viral transcription.

Philipp A Ilinykh1, Bersabeh Tigabu1, Andrey Ivanov2, Tatiana Ammosova3, Yuri Obukhov2, Tania Garron4, Namita Kumari2, Dmytro Kovalskyy5, Maxim O Platonov5, Vasiliy S Naumchik5, Alexander N Freiberg1, Sergei Nekhai6, Alexander Bukreyev7.   

Abstract

The filovirus Ebola (EBOV) causes the most severe hemorrhagic fever known. The EBOV RNA-dependent polymerase complex includes a filovirus-specific VP30, which is critical for the transcriptional but not replication activity of EBOV polymerase; to support transcription, VP30 must be in a dephosphorylated form. Here we show that EBOV VP30 is phosphorylated not only at the N-terminal serine clusters identified previously but also at the threonine residues at positions 143 and 146. We also show that host cell protein phosphatase 1 (PP1) controls VP30 dephosphorylation because expression of a PP1-binding peptide cdNIPP1 increased VP30 phosphorylation. Moreover, targeting PP1 mRNA by shRNA resulted in the overexpression of SIPP1, a cytoplasm-shuttling regulatory subunit of PP1, and increased EBOV transcription, suggesting that cytoplasmic accumulation of PP1 induces EBOV transcription. Furthermore, we developed a small molecule compound, 1E7-03, that targeted a non-catalytic site of PP1 and increased VP30 dephosphorylation. The compound inhibited the transcription but increased replication of the viral genome and completely suppressed replication of EBOV in cultured cells. Finally, mutations of Thr(143) and Thr(146) of VP30 significantly inhibited EBOV transcription and strongly induced VP30 phosphorylation in the N-terminal Ser residues 29-46, suggesting a novel mechanism of regulation of VP30 phosphorylation. Our findings suggest that targeting PP1 with small molecules is a feasible approach to achieve dysregulation of the EBOV polymerase activity. This novel approach may be used for the development of antivirals against EBOV and other filovirus species.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Ebola Virus; Phosphoprotein Phosphatase 1 (PP1); Small Molecule; Transcription; Viral Replication

Mesh:

Substances:

Year:  2014        PMID: 24936058      PMCID: PMC4132779          DOI: 10.1074/jbc.M114.575050

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription.

Authors:  A Bermingham; P L Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture.

Authors:  Gabriele Neumann; Heinz Feldmann; Shinji Watanabe; Igor Lukashevich; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes.

Authors:  E Mühlberger; B Lötfering; H D Klenk; S Becker
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

4.  Termini of all mRNA species of Marburg virus: sequence and secondary structure.

Authors:  E Mühlberger; S Trommer; C Funke; V Volchkov; H D Klenk; S Becker
Journal:  Virology       Date:  1996-09-15       Impact factor: 3.616

5.  Isolation and characterization of PNUTS, a putative protein phosphatase 1 nuclear targeting subunit.

Authors:  P B Allen; Y G Kwon; A C Nairn; P Greengard
Journal:  J Biol Chem       Date:  1998-02-13       Impact factor: 5.157

6.  The C-terminus of NIPP1 (nuclear inhibitor of protein phosphatase-1) contains a novel binding site for protein phosphatase-1 that is controlled by tyrosine phosphorylation and RNA binding.

Authors:  M Beullens; V Vulsteke; A Van Eynde; I Jagiello; W Stalmans; M Bollen
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

7.  Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus.

Authors:  P L Collins; M G Hill; J Cristina; H Grosfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

8.  Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening.

Authors:  Jonathan S Towner; Jason Paragas; Jason E Dover; Manisha Gupta; Cynthia S Goldsmith; John W Huggins; Stuart T Nichol
Journal:  Virology       Date:  2005-02-05       Impact factor: 3.616

9.  Determination of phosphorylated residues from human respiratory syncytial virus P protein that are dynamically dephosphorylated by cellular phosphatases: a possible role for serine 54.

Authors:  Ana Asenjo; Lorena Rodríguez; Nieves Villanueva
Journal:  J Gen Virol       Date:  2005-04       Impact factor: 3.891

10.  Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems.

Authors:  E Mühlberger; M Weik; V E Volchkov; H D Klenk; S Becker
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more
  42 in total

1.  Predictive and comparative analysis of Ebolavirus proteins.

Authors:  Qian Cong; Jimin Pei; Nick V Grishin
Journal:  Cell Cycle       Date:  2015-07-09       Impact factor: 4.534

Review 2.  Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.

Authors:  Colm Atkins; Alexander N Freiberg
Journal:  Future Virol       Date:  2017-10-23       Impact factor: 1.831

3.  Global phosphoproteomic analysis of Ebola virions reveals a novel role for VP35 phosphorylation-dependent regulation of genome transcription.

Authors:  Andrey Ivanov; Palaniappan Ramanathan; Christian Parry; Philipp A Ilinykh; Xionghao Lin; Michael Petukhov; Yuri Obukhov; Tatiana Ammosova; Gaya K Amarasinghe; Alexander Bukreyev; Sergei Nekhai
Journal:  Cell Mol Life Sci       Date:  2019-09-28       Impact factor: 9.261

4.  Human cytomegalovirus phosphoproteins are hypophosphorylated and intrinsically disordered.

Authors:  Franz J J Rieder; Marie-Theres Kastner; Markus Hartl; Martin G Puchinger; Martina Schneider; Otto Majdic; William J Britt; Kristina Djinović-Carugo; Christoph Steininger
Journal:  J Gen Virol       Date:  2017-04-01       Impact factor: 3.891

5.  High-Throughput Minigenome System for Identifying Small-Molecule Inhibitors of Ebola Virus Replication.

Authors:  Megan R Edwards; Colette Pietzsch; Thibaut Vausselin; Megan L Shaw; Alexander Bukreyev; Christopher F Basler
Journal:  ACS Infect Dis       Date:  2015-06-24       Impact factor: 5.084

6.  Protein phosphatase 1 abrogates IRF7-mediated type I IFN response in antiviral immunity.

Authors:  Ling Wang; Juan Zhao; Junping Ren; Kenton H Hall; Jonathan P Moorman; Zhi Q Yao; Shunbin Ning
Journal:  Eur J Immunol       Date:  2016-08-29       Impact factor: 5.532

7.  Therapeutics for postexposure treatment of Ebola virus infection.

Authors:  Marina Jerebtsova; Sergei Nekhai
Journal:  Future Virol       Date:  2015-03       Impact factor: 1.831

8.  Protein Phosphatase 1α Interacts with Venezuelan Equine Encephalitis Virus Capsid Protein and Regulates Viral Replication through Modulation of Capsid Phosphorylation.

Authors:  Brian D Carey; Tatiana Ammosova; Chelsea Pinkham; Xionghao Lin; Weidong Zhou; Lance A Liotta; Sergei Nekhai; Kylene Kehn-Hall
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

9.  Dynamic Phosphorylation of VP30 Is Essential for Ebola Virus Life Cycle.

Authors:  Nadine Biedenkopf; Clemens Lier; Stephan Becker
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

10.  Protein Phosphatase-1 regulates Rift Valley fever virus replication.

Authors:  Alan Baer; Nazly Shafagati; Ashwini Benedict; Tatiana Ammosova; Andrey Ivanov; Ramin M Hakami; Kaori Terasaki; Shinji Makino; Sergei Nekhai; Kylene Kehn-Hall
Journal:  Antiviral Res       Date:  2016-01-20       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.